News

Free Webinar Planned for Those Interested in Referring or Applying to NIH Undiagnosed Diseases Network


 

References

The Undiagnosed Diseases Network (UDN), a research project supported by the National Institutes of Health (NIH) Common Fund, brings together clinical and research experts from across the country to try to solve the most challenging medical mysteries. As part of this project, patients with longstanding unexplained symptoms can apply to receive an in-depth clinical and research examination at one of the UDN’s seven medical centers.

The National Organization for Rare Disorders (NORD) and the UDN will co-host a free webinar from 1 to 2 p.m. ET on Friday, June 3, for clinicians, researchers, and patients that will provide an overview of the UDN, discuss the application and evaluation process, and review financial considerations. Participants will also have the opportunity to hear from a patient who has been through the UDN clinical and research evaluation.

Speakers will include Katrina Dipple, MD, PhD, Departments of Human Genetics and Pediatrics, University of California, Los Angeles; Vandana Shashi, MD, Department of Pediatrics, Duke University Medical Center; Kimberly Splinter, MS, CGC, Genetic Counselor and Clinical Project Manager, UDN Coordinating Center, Harvard Medical School.

Register here for this free webinar. Questions may be directed to education@rarediseases.org.

Recommended Reading

NORD Announces 2016 Rare Impact Award Recipients
MDedge Dermatology
Free Summer Camp For Families of Children With Rare Diseases
MDedge Dermatology
NORD Speaks on Behalf of Continued Funding for NIH Undiagnosed Diseases Network
MDedge Dermatology
NIH and FDA Release a Draft Clinical Trial Protocol Template for Public Discussion
MDedge Dermatology
News From NORD Round-Up: April 2016
MDedge Dermatology
Tofacitinib an alternative treatment for refractory cutaneous dermatomyositis
MDedge Dermatology
Brodalumab effective for rare, severe types of psoriasis
MDedge Dermatology
Macitentan falls short to stop digital ulcers in systemic sclerosis
MDedge Dermatology
FDA: Olanzapine can cause serious skin reaction
MDedge Dermatology
Study lays groundwork for refractory cutaneous lupus treatment algorithms
MDedge Dermatology